Tukysa

News

Pfizer's Tukysa greenlit for earlier use in breast cancer

Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.

News

Pfizer makes first-line case for Tukysa in breast cancer

Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

News

Can new Tukysa data drop unlock its sales potential?

A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.

News

Seagen posts breast cancer win ahead of Pfizer takeover

The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone a

News

Forget Merck, now Pfizer is said to be after Seagen

Rumour of negotiations comes as Pfizer is facing a steep patent cliff in the next few years.

News

AZ, Daiichi challenge Roche with EU okay for earlier use of ...

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive metastatic breast cancer, moving the drug up the treatment pathway.

Pfizer's Tukysa greenlit for earlier use in breast cancer

Pfizer makes first-line case for Tukysa in breast cancer

Can new Tukysa data drop unlock its sales potential?

Seagen posts breast cancer win ahead of Pfizer takeover

Forget Merck, now Pfizer is said to be after Seagen

AZ, Daiichi challenge Roche with EU okay for earlier use of ...

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Tukysa

Editor's Picks